about
Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosisImmunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsImpact of Exercise on Innate Immunity in Multiple Sclerosis Progression and SymptomatologyAlemtuzumab for the treatment of relapsing-remitting multiple sclerosis.Aggressive multiple sclerosis: proposed definition and treatment algorithm.The meninges: new therapeutic targets for multiple sclerosis.Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein.Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Immune competence after alemtuzumab treatment of multiple sclerosis.Disease modification in multiple sclerosis: an update.Current evaluation of alemtuzumab in multiple sclerosis.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.Regulation of human glia by multiple sclerosis disease modifying therapies.Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.Emerging biological therapies for the treatment of myelodysplastic syndromes.Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.Impact of Immune-Modulatory Drugs on Regulatory T Cell.Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.Regulation unmasked by activation.Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.Alemtuzumab depletion failure can occur in multiple sclerosis.Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
P2860
Q24200823-E3B4567C-2BE6-4007-954F-C42E24827D53Q26738810-60A5230A-12D9-4925-81C9-66CF9F6E2C07Q26745562-9F65FAA0-8DCD-4330-8009-E92221CDD8AFQ30808014-369C8635-041A-4AFD-9C6F-311DB47A30C2Q34478828-B9F36592-55C6-4286-A1C7-683818607445Q35584727-213655DD-376B-4590-BC7C-B3207B948059Q35680158-F980669F-5D31-4D84-9B0D-27667F8EB880Q36215626-834DDD3F-C3F9-4A40-91E0-640AB03CAF1DQ36399264-E6A970B1-CF29-4A3E-BBD4-9C04C7FE5C38Q36975701-37CAA945-7347-454E-8274-C025F66F74F8Q37451106-E4644B3D-3D07-4104-B2B5-DB1FF1772A99Q38150823-70BC8736-E085-4057-A181-C62EC1789644Q38167350-952F92FA-B3F3-4CAD-90CD-2399A7A03E02Q38364547-DE901484-8E10-48A3-9BD4-E36B4588FF0CQ38563863-1C76FE09-10BB-4248-9FA9-78C541598679Q38815391-B0A31F03-B921-4B17-98FF-382AB0F34ABDQ38834981-C549FE9A-F8F1-4772-912A-D3C28FCD835EQ38840423-A2B0E230-7893-4BE4-9152-454D4BFA6839Q38918124-935057D2-98A8-4B1F-BD97-960761F5738DQ38960854-5430D90B-8148-4416-A2DB-A8CB10DD5B7AQ44475978-6ACD660F-7894-4C23-8188-B27ECC914BCAQ44566466-C75AF339-8129-4EF1-92B7-185227A3E16FQ47409416-739E47A4-C866-4158-AC72-19095538DE3EQ48106234-A06C58C5-F470-4D24-AA31-C5C26B2B29EBQ49712050-ABC0C331-F417-4A4B-AE31-B5F7C143883EQ50034109-A87F453A-D59E-420F-AB07-D0992CCAE903Q58555322-B1E65FEA-AE71-4C31-892F-798F33217774
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Alemtuzumab therapy for multiple sclerosis.
@ast
Alemtuzumab therapy for multiple sclerosis.
@en
type
label
Alemtuzumab therapy for multiple sclerosis.
@ast
Alemtuzumab therapy for multiple sclerosis.
@en
prefLabel
Alemtuzumab therapy for multiple sclerosis.
@ast
Alemtuzumab therapy for multiple sclerosis.
@en
P2860
P1433
P1476
Alemtuzumab therapy for multiple sclerosis.
@en
P2093
Alasdair J Coles
P2860
P2888
P356
10.1007/S13311-012-0159-0
P577
2013-01-01T00:00:00Z